Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-973 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive a single dose of VX-973 under fasted conditions. |
| Part B: Multiple Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive multiple doses of VX-973 under fasted conditions. |
| Placebo Part A | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-973. |
| Placebo Part B | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-973. |
| Name | Type | Description |
|---|---|---|
| VX-973 | DRUG | Suspension for oral administration. |
| Placebo | DRUG | Suspension for oral administration. |
| Midazolam | DRUG | Syrup for oral administration. |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2) * A total body weight of more than (\>) 50 kg * Participants of non-childbearing potential * Nonsmoker or ex-smoker for at least 3 months before screening Key Exclusion Criteria: * History of febri...
VX-973 is an investigational small molecule being developed for the treatment of pain. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its safety and tolerability.
VX-973 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and tolerability in healthy volunteers.
VX-973 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 dose escalation studies have been completed, both involving healthy adult volunteers.
VX-973 has completed two Phase 1 clinical trials. The first, NCT05866055, was a dose escalation study in healthy adults in the United Kingdom. The second, NCT06615570, was a dose escalation study in healthy participants in the United States. Both trials enrolled 30 participants each.
No alternative names for VX-973 have been disclosed. The drug is identified solely by its code name VX-973 in clinical trial registrations and is being developed by Vertex Pharmaceuticals for the treatment of pain.